<DOC>
	<DOCNO>NCT00321100</DOCNO>
	<brief_summary>The purpose study determine objective response rate patient previously untreated metastatic colorectal cancer treat combination cetuximab , capecitabine , oxaliplatin without bevacizumab .</brief_summary>
	<brief_title>Combination Cetuximab , Capecitabine , Oxaliplatin With Without Bevacizumab</brief_title>
	<detailed_description>Research show drug treatment patient cancer colon rectum receive , longer live . One use drug capecitabine oxaliplatin patient study receive . Bevacizumab antibody block blood flow tumor increase long patient colorectal cancer live . However , increase risk stroke heart attack . Bevacizumab currently standard part treatment colorectal cancer . Cetuximab antibody block protein call EGFR shrink colorectal cancer . It may helpful initial chemotherapy bevacizumab . One goal study find response rate ( chance tumor shrink ) two treatment colorectal cancer . All patient get capecitabine , oxaliplatin cetuximab . Half receive bevacizumab . All drug study approve treat colorectal cancer . This research study do find best , safe way combine therapy .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>measurable metastatic adenocarcinoma colon rectum prior systemic therapy metastatic disease adjuvant therapy must complete &gt; /=12 month prior recurrence , prior radiotherapy permit must complete &gt; 6 month prior study entry must tumor tissue available EGFR thymidine phosphorylase evaluation ECOG PS 01 age &gt; /= 18 adequate organ function : WBC &gt; /=3,000 , ANC &gt; /=1,500 , platelets &gt; /= 100,000 , total bilirubin &lt; /= 1.5X ULN , AST &amp; ALT &lt; /= 2.5X ULN , create clearance &gt; /= 50mL/min negative pregnancy test w/in 72 hour treatment woman child bear potential ability understand willing sign write ICF able swallow absorb oral medication medical psychiatric condition would potentially pose risk patient participation ( i.e . limit : uncontrolled hypertension , MI w/in 6 month , CNS disease , pregnancy nursing ) history neoplasm ( nonmetastatic skin cancer carcinoma situ cervix ) w/in 5 year surgical procedure ( include close biopsy access port placement ) , open biopsy , significant traumatic injury w/in 28 day registration anticipation need surgical procedure study , fine needle aspiration core biopsy w/in 7 day registration urine protein : creatinine ration &gt; /=1.0 screen evidence bleed diathesis coagulopathy ( absence anticoagulation ) prior severe infusion reaction MAB allergic reaction capecitabine oxaliplatin underlie neuropathy &gt; /= grade 2 TIA CVA w/in 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>metastatic</keyword>
	<keyword>colorectal</keyword>
	<keyword>cancer</keyword>
	<keyword>initial therapy</keyword>
</DOC>